Novel therapeutic targets in the brain tumor microenvironment

Oncotarget

Volumn 3, Issue 5, 2012, Pages 568-575

  Phillips, Joanna J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Glioblastoma; HSPG; Proteoglycans; Sulf2; Sulfs; Tumor microenvironment

Indexed keywords

HEPARANASE; PROTEOHEPARAN SULFATE; SULFATASE; SULFATASE 1; SULFATASE 2; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTICLE; BRAIN TUMOR; CANCER CELL; CANCER INVASION; CARCINOGENESIS; CELL PROLIFERATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME MODIFICATION; EXTRACELLULAR SPACE; GLIOBLASTOMA; INTRACELLULAR SIGNALING; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; CELL TRANSFORMATION; DRUG EFFECT; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; BRAIN NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; WNT PROTEINS;

EID: 84867294546     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.526     Document Type: Article

References (71)

1. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A and Holland E. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One. 2009; 4(11):e7752.
2. Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, Popoff S, Nutt CL, Louis DN, Cairncross JG, Gilbert MR, Phillips HS, Mehta MP, Chakravarti A, Pelloski CE, Bhat K, et al. A multigene predictor of outcome in glioblastoma. Neuro Oncol. 2010; 12(1):49-57.
3. Mischel PS, Shai R, Shi T, Horvath S, Lu KV, Choe G, Seligson D, Kremen TJ, Palotie A, Liau LM, Cloughesy TF and Nelson SF. Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene. 2003; 22(15):2361-2373.
4. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG and Aldape K. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006; 9(3):157-173.
5. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110.
6. Bhat KP, Salazar KL, Balasubramaniyan V, Wani K, Heathcock L, Hollingsworth F, James JD, Gumin J, Diefes KL, Kim SH, Turski A, Azodi Y, Yang Y, Doucette T, Colman H, Sulman EP, et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev. 2011; 25(24):2594-2609.
7. Paugh BS, Qu C, Jones C, Liu Z, Adamowicz-Brice M, Zhang J, Bax DA, Coyle B, Barrow J, Hargrave D, Lowe J, Gajjar A, Zhao W, Broniscer A, Ellison DW, Grundy RG, et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol. 2010; 28(18):3061-3068.
8. Duarte CW, Willey CD, Zhi D, Cui X, Harris JJ, Vaughan LK, Mehta T, McCubrey RO, Khodarev NN, Weichselbaum RR and Gillespie GY. Expression signature of IFN/ STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific manner. PloS One. 2012; 7(1):e29653.
9. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109.
10. Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin CH, Westermark B and Nister M. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res. 1992; 52(11):3213-3219.
11. Ozawa T, Brennan CW, Wang L, Squatrito M, Sasayama T, Nakada M, Huse JT, Pedraza A, Utsuki S, Yasui Y, Tandon A, Fomchenko EI, Oka H, Levine RL, Fujii K, Ladanyi M, et al. PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev. 2010; 24(19):2205-2218.
12. Guha A, Dashner K, Black PM, Wagner JA and Stiles CD. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int J Cancer. 1995; 60(2):168-173.
13. Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN and Holland EC. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev. 2001; 15(15):1913-1925.
14. Uhrbom L, Hesselager G, Nister M and Westermark B. Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res. 1998; 58(23):5275-5279.
15. Liu KW, Feng H, Bachoo R, Kazlauskas A, Smith EM, Symes K, Hamilton RL, Nagane M, Nishikawa R, Hu B and Cheng SY. SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans. J Clin Invest. 2011; 121(3):905-917.
16. Fan QW and Weiss WA. Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance. Cur Top Microbiol Immunol. 2010; 347:279-296.
17. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, Chin L and DePinho RA. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science. 2007; 318(5848):287-290.
18. Hegi ME, Diserens AC, Bady P, Kamoshima Y, Kouwenhoven MC, Delorenzi M, Lambiv WL, Hamou MF, Matter MS, Koch A, Heppner FL, Yonekawa Y, Merlo A, Frei K, Mariani L and Hofer S. Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial. Mol Cancer Ther. 2011; 10(6):1102-1112.
19. Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, Davidson CJ, Akhavanfard S, Cahill DP, Aldape KD, Betensky RA, Louis DN and Iafrate AJ. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell. 2011; 20(6):810-817.
20. Dhoot GK, Gustafsson MK, Ai X, Sun W, Standiford DM and Emerson CP, Jr. Regulation of Wnt signaling and embryo patterning by an extracellular sulfatase. Science. 2001; 293(5535):1663-1666.
21. Logan CY and Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004; 20:781-810.
22. Steck PA, Moser RP, Bruner JM, Liang L, Freidman AN, Hwang TL and Yung WK. Altered expression and distribution of heparan sulfate proteoglycans in human gliomas. Cancer Res. 1989; 49(8):2096-2103.
23. Watanabe A, Mabuchi T, Satoh E, Furuya K, Zhang L, Maeda S and Naganuma H. Expression of syndecans, a heparan sulfate proteoglycan, in malignant gliomas: participation of nuclear factor-kappaB in upregulation of syndecan-1 expression. J Neurooncol. 2006; 77(1):25-32.
24. Smith EM, Mitsi M, Nugent MA and Symes K. PDGF-A interactions with fibronectin reveal a critical role for heparan sulfate in directed cell migration during Xenopus gastrulation. Proc Natl Acad Sci U S A. 2009; 106(51):21683-21688.
25. Feyzi E, Lustig F, Fager G, Spillmann D, Lindahl U and Salmivirta M. Characterization of heparin and heparan sulfate domains binding to the long splice variant of platelet-derived growth factor A chain. J Biol Chem. 1997; 272(9):5518-5524.
26. Ono K, Hattori H, Takeshita S, Kurita A and Ishihara M. Structural features in heparin that interact with VEGF165 and modulate its biological activity. Glycobiology. 1999; 9(7):705-711.
27. Kreuger J, Salmivirta M, Sturiale L, Gimenez-Gallego G and Lindahl U. Sequence analysis of heparan sulfate epitopes with graded affinities for fibroblast growth factors 1 and 2. J Biol Chem. 2001; 276(33):30744-30752.
28. Ashikari-Hada S, Habuchi H, Kariya Y, Itoh N, Reddi AH and Kimata K. Characterization of growth factorbinding structures in heparin/heparan sulfate using an octasaccharide library. J Biol Chem. 2004; 279(13):12346-12354.
29. Ai X, Do AT, Lozynska O, Kusche-Gullberg M, Lindahl U and Emerson CP, Jr. QSulf1 remodels the 6-O sulfation states of cell surface heparan sulfate proteoglycans to promote Wnt signaling. J Cell Biol. 2003; 162(2):341-351.
30. Gallagher JT. Heparan sulfate: growth control with a restricted sequence menu. J Clin Invest. 2001; 108(3):357-361.
31. Sarrazin S, Lamanna WC and Esko JD. Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol. 2011; 3(7).
32. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J and Zako M. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem. 1999; 68:729-777.
33. Bink RJ, Habuchi H, Lele Z, Dolk E, Joore J, Rauch GJ, Geisler R, Wilson SW, den Hertog J, Kimata K and Zivkovic D. Heparan sulfate 6-o-sulfotransferase is essential for muscle development in zebrafish. J Biol Chem. 2003; 278(33):31118-31127.
34. Bulow HE and Hobert O. Differential sulfations and epimerization define heparan sulfate specificity in nervous system development. Neuron. 2004; 41(5):723-736.
35. Kamimura K, Fujise M, Villa F, Izumi S, Habuchi H, Kimata K and Nakato H. Drosophila heparan sulfate 6-O-sulfotransferase (dHS6ST) gene. Structure, expression, and function in the formation of the tracheal system. J Biol Chem. 2001; 276(20):17014-17021.
36. Esko JD and Lindahl U. Molecular diversity of heparan sulfate. J Clin Invest. 2001; 108(2):169-173.
37. Habuchi H, Habuchi O and Kimata K. Sulfation pattern in glycosaminoglycan: does it have a code? Glycoconj J. 2004; 21(1-2):47-52.
38. Danesin C, Agius E, Escalas N, Ai X, Emerson C, Cochard P and Soula C. Ventral neural progenitors switch toward an oligodendroglial fate in response to increased Sonic hedgehog (Shh) activity: involvement of Sulfatase 1 in modulating Shh signaling in the ventral spinal cord. J Neurosci. 2006; 26(19):5037-5048.
39. Ai X, Kitazawa T, Do AT, Kusche-Gullberg M, Labosky PA and Emerson CP, Jr. SULF1 and SULF2 regulate heparan sulfate-mediated GDNF signaling for esophageal innervation. Development. 2007; 134(18):3327-3338.
40. Phillips JJ, Huillard E, Robinson AE, Ward A, Lum DH, Polley MY, Rosen SD, Rowitch DH and Werb Z. Heparan sulfate sulfatase SULF2 regulates PDGFR-alpha signaling and growth in human and mouse malignant glioma. J Clin Invest. 2012; 122(3):911-922.
41. Bret C, Moreaux J, Schved JF, Hose D and Klein B. SULFs in human neoplasia: implication as progression and prognosis factors. J Transl Med. 2011; 9:72.
42. Rosen SD and Lemjabbar-Alaoui H. Sulf-2: an extracellular modulator of cell signaling and a cancer target candidate. Expert Opin Ther Targets. 2010; 14(9):935-949.
43. Lemjabbar-Alaoui H, van Zante A, Singer MS, Xue Q, Wang YQ, Tsay D, He B, Jablons DM and Rosen SD. Sulf-2, a heparan sulfate endosulfatase, promotes human lung carcinogenesis. Oncogene. 2009; 29(5):635-646.
44. Nawroth R, van Zante A, Cervantes S, McManus M, Hebrok M and Rosen SD. Extracellular sulfatases, elements of the Wnt signaling pathway, positively regulate growth and tumorigenicity of human pancreatic cancer cells. PLoS One. 2007; 2(4):e392.
45. Lai JP, Oseini AM, Moser CD, Yu C, Elsawa SF, Hu C, Nakamura I, Han T, Aderca I, Isomoto H, Garrity-Park MM, Shire AM, Li J, Sanderson SO, Adjei AA, Fernandez-Zapico ME, et al. The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation. Hepatology. 2010; 52(5):1680-1689.
46. Johansson FK, Brodd J, Eklof C, Ferletta M, Hesselager G, Tiger CF, Uhrbom L and Westermark B. Identification of candidate cancer-causing genes in mouse brain tumors by retroviral tagging. Proc Natl Acad Sci U S A. 2004; 101(31):11334-11337.
47. Hong X, Nelson KK, deCarvalho AC and Kalkanis SN. Heparanase expression of glioma in human and animal models. J Neurosurg. 2010; 113(2):261-269.
48. Ridgway LD, Wetzel MD and Marchetti D. Heparanase Modulates Shh and Wnt3a Signaling in Human Medulloblastoma Cells. Exp Ther Med. 2011; 2(2):229-238.
49. Kurokawa H, Katsube K, Podyma KA, Ikuta M, Iseki H, Nakajima M, Akashi T, Omura K, Takagi M and Yanagishita M. Heparanase and tumor invasion patterns in human oral squamous cell carcinoma xenografts. Cancer Sci. 2003; 94(3):277-285.
50. Rapraeger AC. Syndecan-regulated receptor signaling. J Cell Biol. 2000; 149(5):995-998.
51. Whiteford JR, Xian X, Chaussade C, Vanhaesebroeck B, Nourshargh S and Couchman JR. Syndecan-2 is a novel ligand for the protein tyrosine phosphatase receptor CD148. Mol Biol Cell. 2011; 22(19):3609-3624.
52. Derksen PW, Keehnen RM, Evers LM, van Oers MH, Spaargaren M and Pals ST. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood. 2002; 99(4):1405-1410.
53. Ramani VC, Yang Y, Ren Y, Nan L and Sanderson RD. Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity. J Biol Chem. 2011; 286(8):6490-6499.
54. Alexander CM, Reichsman F, Hinkes MT, Lincecum J, Becker KA, Cumberledge S and Bernfield M. Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice. Nat Genet. 2000; 25(3):329-332.
55. Hayashida K, Parks WC and Park PW. Syndecan-1 shedding facilitates the resolution of neutrophilic inflammation by removing sequestered CXC chemokines. Blood. 2009; 114(14):3033-3043.
56. Seidel C, Sundan A, Hjorth M, Turesson I, Dahl IM, Abildgaard N, Waage A and Borset M. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood. 2000; 95(2):388-392.
57. Yang Y, Yaccoby S, Liu W, Langford JK, Pumphrey CY, Theus A, Epstein J and Sanderson RD. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood. 2002; 100(2):610-617.
58. Su G, Meyer K, Nandini CD, Qiao D, Salamat S and Friedl A. Glypican-1 is frequently overexpressed in human gliomas and enhances FGF-2 signaling in glioma cells. Am J Pathol. 2006; 168(6):2014-2026.
59. Parish CR. The role of heparan sulphate in inflammation. Nat Rev Immunol. 2006; 6(9):633-643.
60. Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, Luo JL and Karin M. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature. 2009; 457(7225):102-106.
61. Zhou H, Roy S, Cochran E, Zouaoui R, Chu CL, Duffner J, Zhao G, Smith S, Galcheva-Gargova Z, Karlgren J, Dussault N, Kwan RY, Moy E, Barnes M, Long A, Honan C, et al. M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis. PloS One. 2011; 6(6):e21106.
62. Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, Nelson SF and Liau LM. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res. 2011; 17(6):1603-1615.
63. Nister M, Libermann TA, Betsholtz C, Pettersson M, Claesson-Welsh L, Heldin CH, Schlessinger J and Westermark B. Expression of messenger RNAs for plateletderived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines. Cancer Res. 1988; 48(14):3910-3918.
64. Carapancea M, Cosaceanu D, Budiu R, Kwiecinska A, Tataranu L, Ciubotaru V, Alexandru O, Banita M, Pisoschi C, Backlund ML, Lewensohn R and Dricu A. Dual targeting of IGF-1R and PDGFR inhibits proliferation in highgrade gliomas cells and induces radiosensitivity in JNK-1 expressing cells. J Neurooncol. 2007; 85(3):245-254.
65. Liu TJ, LaFortune T, Honda T, Ohmori O, Hatakeyama S, Meyer T, Jackson D, de Groot J and Yung WK. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther. 2007; 6(4):1357-1367.
66. Dredge K, Hammond E, Handley P, Gonda TJ, Smith MT, Vincent C, Brandt R, Ferro V and Bytheway I. PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. Br J Cancer. 2011; 104(4):635-642.
67. Hossain MM, Hosono-Fukao T, Tang R, Sugaya N, van Kuppevelt TH, Jenniskens GJ, Kimata K, Rosen SD and Uchimura K. Direct detection of HSulf-1 and HSulf-2 activities on extracellular heparan sulfate and their inhibition by PI-88. Glycobiology. 2010; 20(2):175-186.
68. Johnstone KD, Karoli T, Liu L, Dredge K, Copeman E, Li CP, Davis K, Hammond E, Bytheway I, Kostewicz E, Chiu FC, Shackleford DM, Charman SA, Charman WN, Harenberg J, Gonda TJ, et al. Synthesis and biological evaluation of polysulfated oligosaccharide glycosides as inhibitors of angiogenesis and tumor growth. J Med Chem. 2010; 53(4):1686-1699.
69. Joyce JA, Freeman C, Meyer-Morse N, Parish CR and Hanahan D. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene. 2005; 24(25):4037-4051.
70. Liu CJ, Lee PH, Lin DY, Wu CC, Jeng LB, Lin PW, Mok KT, Lee WC, Yeh HZ, Ho MC, Yang SS, Lee CC, Yu MC, Hu RH, Peng CY, Lai KL, et al. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol. 2009; 50(5):958-968.
71. The Cancer Genome Atlas. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455(7216):1061-1068.